PTRA enables clinicians to confidently personalize immunosuppression, reducing adverse events in low-risk patients while strengthening protection against rejection in high-risk patients
Health economic analysis shows potential to save more than $191 million across U.S. for patients preparing for kidney transplant
FRANKLIN, Tenn., July 27, 2026 — Verici Dx, a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a health economic cost impact analysis demonstrating the significant potential cost benefit of the Pre-Transplant Risk Assessment (PTRA™) test for predicting early acute rejection (EAR) in kidney transplant. The study, entitled “Cost Impact of a Novel Pre-transplant Risk Assessment Tool for Early Acute Rejection in Kidney Transplant Patients” and published in the Journal of Health Economics and Outcomes Research, shows that integrating PTRA into standard clinical practice could generate substantial healthcare savings while supporting more personalized immunosuppression strategies.
Key findings of the study, conducted by Avalon Health Economics, included the potential for more than $191 million in healthcare savings across the U.S. standard-risk kidney transplant population over two years
“Kidney transplant recipients require carefully managed immunosuppressive therapy to prevent rejection while minimizing complications due to immunosuppression associated infections, adverse drug events, or malignancies,” said Sara Barrington, Chief Executive Officer of Verici Dx. “However, clinicians currently lack robust tools to accurately stratify patient risk prior to transplantation. This publication highlights the substantial value that a precision diagnostic like PTRA can bring to transplant medicine, supporting more informed clinical decisions, improving patient management, and potentially saving the healthcare system millions of dollars.”
The PTRA test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, and immune pathways associated with both T cell– and antibody-mediated mechanisms of rejection. By identifying patients at higher or lower risk, clinicians can tailor immunosuppressive regimens to better match individual immune risk profiles. The PTRA test is commercially marketed by Thermo Fisher Scientific.
The authors note that more intense immunosuppression is often used in patients without clear high-risk characteristics. Based on their study, the authors conclude that incorporating the PTRA test in standard-of-care protocols may allow clinicians to more confidently tailor immunosuppression at a reduced level, reducing medication-related adverse events and unfavorable clinical outcomes. The approach may also allow for more intense immunosuppression for some patients with a high-risk PTRA result, reducing acute rejection and its downstream effects.
“Early acute rejection remains one of the most significant drivers of post-transplant complications, graft injury, and healthcare costs,” said Beatrice Concepcion, MD, Medical Director, Kidney and Pancreas Transplant, University of Chicago Medicine. “Having the ability to stratify rejection risk before transplantation could meaningfully change how we approach immunosuppression. The PTRA test has the potential to help clinicians personalize therapy, escalating treatment for patients who truly need it while avoiding unnecessary exposure in lower-risk patients.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
The Pre-Transplant Risk Assessment (PTRA) test is a laboratory developed test, and its performance characteristics determined by the CLIA laboratory performing the test. It has not been cleared or approved by the U.S. Food and Drug Administration or CE marked in the EU.
New experts join four current advisors, bringing together leading voices across transplant medicine, surgery, and data science
Franklin, TN – July 23, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced an expansion of its Scientific Advisory Board (SAB), appointing 14 new members who will join four current advisors. The new SAB members represent exceptional breadth and depth of expertise across nephrology, transplant surgery, pathology, immunology, and biostatistics. Together with existing Board members, they form a group of highly respected leaders in the transplant community known for generating rigorous, high-quality scientific evidence and shaping clinical practice. The SAB will continue to be chaired by Lorenzo Gallon, MD, Professor of Medicine and Surgery and Director of the Abdominal Organ Transplant Program at the University of Illinois School of Medicine.
This distinguished and influential group reflects Verici Dx’s commitment to advancing innovative, validated solutions designed to improve transplant outcomes.
“The addition of these distinguished experts, spanning clinicians, surgeons, and data scientists, brings an exceptional level of insight and real-world experience,” said Dr. Gallon. “Their collective expertise will be instrumental in guiding Verici’s scientific strategy, supporting ongoing clinical development, and accelerating the adoption of precision diagnostics in transplant care.”
Among the newly appointed members is Henry Randall, MD, a highly regarded transplant surgeon and incoming President of the American Society of Transplant Surgeons, widely recognized for his leadership in applying artificial intelligence in transplantation. His appointment highlights strong endorsement from the surgical community and reinforces the clinical relevance of Verici Dx’s technology.
Newly appointed SAB members include:
- Prince Mohan Anand, MD, FACP, FASN, FAST – Director of Transplant Services, MUSC Health
- Oriol Bestard, MD, PhD – Chief of Nephrology, Vall d’Hebron University Hospital; Research Lead, VHIR
- Antony Chang, MD – Professor, Department of Pathology, University of Chicago
- Aravind Cherukuri, MBBS, PhD, MRCP – Assistant Professor, University of Pittsburgh; Co-Director for Clinical Research, Thomas E. Starzl Transplantation Institute
- Paolo Cravedi, MD, PhD – Associate Professor and Director, Translational Transplant Research Center
- Zahraa Hajjiri, MD – Associate Professor of Clinical Medicine, Medical Director, Transplant Department of Medicine, Division of Nephrology, University of Illinois School of Medicine
- Roslyn B. Mannon, MD, FASN – Professor, University of Nebraska Medical Center; Vice-Chair for Research
- Maarten Naesens, MD, PhD – Transplant nephrologist, University Hospitals Leuven
- Rainer Oberbauer, MD – Director, Department of Nephrology & Dialysis and Transplant Medicine, Medical University of Vienna
- Henry Randall, MD – Executive Director, SSM Health Center for Abdominal Transplantation; Incoming President, ASTS
- Jesse Schold, PhD, M.Stat, M.Ed – Professor, University of Colorado; Director, Center for Outcomes Research and Policy
- Neeraj Singh, MD, FACS, FASRS – Professor and Medical Director, Rutgers Health / Robert Wood Johnson University
- Flavio G. Vincenti, MD – Clinical Professor of Medicine and Surgery, University of California, San Francisco
- Alex Wiseman, MD, FAST – Executive Director of Kidney Transplantation, AdventHealth Transplant, Denver, Colorado
Continuing SAB members include Madhav C. Menon, MD, Yale University; Philip O’Connell, PhD, University of Sydney; Emilio Poggio, MD, Cleveland Clinic; and Weija Zhang, PhD, Albert Einstein College of Medicine.
“We are honored to welcome such an accomplished and diverse group of scientific advisors,” said Sara Barrington, Chief Executive Officer of Verici Dx. “Their leadership and active engagement, particularly among physicians already integrating advanced biomarkers into clinical practice, reflect strong confidence in our approach and tremendous optimism about the future of transplant diagnostics.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia®, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
Franklin, TN – July 21, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the appointment of Paul Pagano, PhD, as Chief of Medical Affairs. In this role, Dr. Pagano will bridge scientific development and commercialization, helping to shape the strategic vision for clinical application of the Company’s transplant diagnostics. He will focus on advancing evidence generation strategies, strengthening medical and scientific communications, and deepening engagement with clinical and academic experts to support the continued adoption and evolution of Verici Dx’s solutions.
“Paul brings an important combination of deep scientific expertise and proven leadership in building and scaling diagnostic organizations,” said Sara Barrington, Chief Executive Officer of Verici Dx. “His experience translating complex science into clinically meaningful products will be invaluable as we continue to expand the impact of our transplant diagnostics portfolio and support clinicians in improving patient outcomes.”
Dr. Pagano has over 20 years of experience across chemistry, engineering, and precision diagnostics. Trained at UCLA in translational research, he has authored multiple publications covering directed evolution, microfluidic lab-on-chip technology, resistance mechanisms in targeted cancer therapy, and early disease detection strategies. Most recently, he served as Chief Executive Officer and Chief Scientific Officer at LungLife AI (LON: LLAI), where he led the development and commercial launch of a best-in-class early lung cancer detection product that was subsequently licensed by a leading liquid biopsy company.
Dr. Pagano earned a BS in Microbiology and Immunology from UC Santa Barbara and a PhD in Pharmacology from the David Geffen School of Medicine at UCLA.
“I am excited to join Verici Dx at a time of impressive growth and continued advancement of its transplant diagnostics portfolio,” said Dr. Pagano. “My goal has always been to drive innovation in healthcare that makes a meaningful impact on patient care, and at Verici Dx I see that happening today. I look forward to working with the team to further strengthen the clinical evidence base and expand the reach of these important diagnostics.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
- Certification from New York, the nation’s most rigorous laboratory evaluation program, extends Tutivia™ authorization to all 50 states, expanding access for clinicians and patients
- Tutivia™ delivers predictive, data-driven intelligence enabling kidney transplant clinicians to proactively optimize treatment options, guide biopsy decisions, and stratify patients according to the risk of graft rejection
Franklin, TN – June 24, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Company also received NY state approval of Tutivia™, its blood-based laboratory developed test (LDT) that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. By detecting rejection-associated biological mechanisms, the Tutivia™ test provides clinicians with a proactive indicator of rejection risk, enabling more precise patient management and risk stratification, better-timed interventions, and the potential to reduce avoidable biopsies and graft loss.
New York is one of the most active kidney transplant locations in the country, with more than 2,000 transplants performed in 2025, underscoring the importance of access to Tutivia™ for clinicians managing complex, high-acuity patients. With this New York state certification, Verici Dx is now authorized to provide laboratory testing services in all 50 U.S. states and the District of Columbia, creating nationwide availability of the Tutivia™ test.
“New York has established one of the most rigorous evaluation processes in the country for LDTs and the laboratories performing those tests,” said Sara Barrington, Chief Executive Officer of Verici Dx. “Receiving certification and test approval from the NYSDOH not only expands access to Tutivia™ for transplant centers in the state, it provides independent validation of our laboratory and data science operations and clinical performance. This milestone ensures our ability to support clinicians nationwide with the predictive intelligence they need to proactively manage complex transplant cases.”
Tutivia™ combines transcriptomics with proprietary machine learning algorithm to deliver predictive intelligence for acute kidney transplant rejection. The test provides clinicians with deeper insight to support more precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemia–reperfusion injury, which can confound conventional blood tests including serum creatinine and cell-free DNA.
“Early identification of rejection biology, before clinical injury occurs, represents a meaningful advance in transplant medicine,” said Pablo C. Loarte-Campos, M.D., Nephrologist and Assistant Professor of Clinical Medicine, Weill Cornell Medical College. “Unlike single-parameter tools such as cell-free DNA that are non-specific, lagging indicators measuring downstream injury, Tutivia™ reflects the biological complexity of transplant patients, enabling sensitive and selective identification of rejection and distinction from other causes of graft dysfunction. New York State approval expands access to this testing for a large and clinically complex transplant population, including high-risk patients for whom conventional biomarkers are often insufficient.”
The science underlying Tutivia™ was pioneered at The Mount Sinai Hospital in New York, one of the world’s leading transplant research centers. Its development is grounded in decades of clinical expertise and scientific rigor, and New York State approval represents a full-circle milestone, bringing a locally developed innovation back to the state’s transplant community with nationwide reach. “Tutivia™ is an example of how discoveries originating at Mount Sinai can be translated into technologies that improve patient care,” said Erik Lium, Ph.D., President of Mount Sinai Innovation Partners at the Icahn School of Medicine at Mount Sinai. “New York State approval is an important milestone that expands access to this innovation for transplant clinicians and patients across the country.”
“In addition to being grounded in rigorous science, the Tutivia™ test was validated in a clinical study that included a broad and diverse transplant patient population, giving clinicians confidence in its performance across the full spectrum of real-world cases,” said Lorenzo Gallon, M.D., Chair of the Verici Dx Scientific Advisory Board and Professor of Medicine and Surgery and Director of the Abdominal Organ Transplant Program at the University of Illinois, Chicago. “By delivering predictive intelligence that captures the biological complexity of transplant rejection, Tutivia™ aligns with how clinicians think and practice, particularly when managing high-risk patient populations.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter, and YouTube.
FRANKLIN, Tenn., June 17, 2026 — Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that collaborators will present new data on the predictive performance of its Tutivia™ test at the American Transplant Congress (ATC) Annual Meeting, taking place June 20–24, 2026 in Boston. The abstracts are available via the planner on the ATC website.
The two poster presentations, delivered by leading transplant clinicians, describe the ability of Tutivia™, a blood-based transcriptomics laboratory developed test (LDT), to predict acute kidney transplant rejection. The test is designed to support more precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemia–reperfusion injury, that can confound conventional monitoring tools, including serum creatinine and cell-free DNA.
Details of the poster presentations are as follows:
Title: Evaluation of Tutivia™ Biomarker for Risk of Acute Rejection in Patients Experiencing Delayed Graft Function
Presenter: Zahraa Fayez Hajjiri, MD, Medical Director, Transplant Nephrology, University of Illinois College of Medicine
Session Date and Time: Tuesday, June 23, 2026 from 2:30 PM – 3:30 PM
Location: Exhibit Hall A
Abstract Number: D107
Title: Tutivia™ Molecular Risk Scores in Relation to BK Viral Activity, BK Virus Nephropathy, and Rejection Phenotypes in Kidney-Transplant Recipients
Presenter: M. Javeed Ansari, MD, Transplant Nephrologist, Northwestern University Feinberg School of Medicine
Session Date and Time: Tuesday, June 23, 2026 from 2:30 PM – 3:30 PM
Location: Exhibit Hall A
Abstract Number: D099
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
Media Relations
Christine Quern
cq@christinequern.com
617-650-8497
- Test outperformed conventional risk metrics in predicting early acute rejection in the first two months following deceased donor kidney transplant
- Enables clinicians in identifying patients who may benefit from safe minimization of therapy while effectively managing risk of early rejection
- Demonstrated to operate mostly independently of donor characteristics, reinforcing the central role of the recipient’s immune phenotype in guiding early transplant care decisions
Franklin, TN – May 19, 2026 – Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Risk Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The study, entitled “A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection” was published in Kidney360. The PTRA test is commercially marketed by Thermo Fisher Scientific.*
“The recipient-specific test enables a more personalized approach to immunosuppression management during the critical early post-transplant period,” said Patti Connolly, Chief Operating Officer of Verici Dx. “PTRA supports clinicians in identification of patients at low immunologic risk of Early Acute Rejection (EAR) which may allow the recipient to be considered for less aggressive immunosuppressive regimens. This risk stratification addresses a critical concern in transplantation, as over-immunosuppression can increase the risk of infection, drug toxicity, and malignancy.”
The test consists of an RNA signature comprised of 29 genes involved in oxidative stress, endothelial injury, metabolic regulation, as well as immune pathways associated with T cell– and antibody-mediated mechanisms of rejection. The test was observed in the clinical validation study to operate mostly independently of donor characteristics, focusing instead on an intrinsic, recipient-specific rejection phenotype, and demonstrates superior performance compared with standard risk features.
PTRA outperformed conventional risk assessment tools, including panel reactive antibodies (PRA) in the ability to predict EAR in the first two months following transplant.
Currently, kidney transplant recipients receive standardized immunosuppressive regimens, with more aggressive therapy often reserved for patients perceived as high-risk, typically based on broad criteria such as high PRA levels. However, these conventional risk features have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy.
Despite decades of progress in transplant medicine, clinicians still rely largely on broad, population-based risk markers that lack the precision needed to guide more individualized care. As a result, immunosuppressive strategies have remained largely one-size-fits-all for more than a decade.
“The data from this study demonstrate that PTRA provides clinically meaningful, recipient-specific risk stratification,” said Beatrice Concepcion, MD, Medical Director, Kidney and Pancreas Transplant, University of Chicago Medicine. “This creates the opportunity to identify low risk patients in whom we may safely reduce immunosuppressive therapy, addressing a long-standing unmet need in transplant medicine. By aiding clinicians in risk assessing recipients, PTRA offers an advancement in support for how we manage immunosuppression.”
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. Operating at the intersection of laboratory and data science, Verici Dx develops complex models to answer the clinical questions that matter most with clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection. The company is headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericibdnewui.fuelvm.com/ and follow us on LinkedIn.
*The Pre-Transplant Rejection Assessment (PTRA) test is a laboratory developed test that is used for clinical purposes by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or CE marked in the EU as an in vitro diagnostic test.
Media Contact
Christine Quern
617-650-8497
cq@christinequern.com